AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28605294 — intervention group
Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine (4 doses of 4mg/1ml for non-sensitive subjects and 4 doses of 2mg/0.5ml for sensitive subjects)
Number of subjects: 24
Study 28605294 — intervention group
Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine (1 booster dose of 2mg/0.5ml)
Number of subjects: 24
Study 28605294 — intervention group
Group type: EXPERIMENTAL
Intervention: CryJ2-LAMP DNA vaccine
Number of subjects: 24
Study 25214645 — intervention group
Group type: COMPARATOR
Intervention: Standard Behavioral Treatment (SBT)
Number of subjects: 38
Study 25214645 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Behavioral Treatment + Enhanced Parenting (SBT + EP)
Number of subjects: 38
Study 24601050 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 10 mg for 10 days during a month for three months
Number of subjects: 45
Study 24601050 — intervention group
Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 45
Study 21390898 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered computerized version of TOMM
Number of subjects: 0
Study 21390898 — intervention group
Group type: COMPARATOR
Intervention: Examiner-administered booklet version of TOMM
Number of subjects: 0
Study 19624323 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate assessment group (completed questionnaires at baseline, 3, 6, and 12 months)
Number of subjects: 147
Study 19624323 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate assessment group
Number of subjects: 147
Study 19624323 — intervention group
Group type: COMPARATOR
Intervention: Delayed assessment group (completed questionnaires only at 12 months)
Number of subjects: 147
Study 17606952 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider intervention sessions
Number of subjects: 100
Study 17606952 — intervention group
Group type: COMPARATOR
Intervention: No provider intervention sessions (Control)
Number of subjects: 100
Study 17606952 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient intervention
Number of subjects: 100
Study 17606952 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients of providers who did not attend intervention)
Number of subjects: 100
Study 15860094 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines with training workshop and educational outreach visit
Number of subjects: 18
Study 15860094 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 18
Study 12398427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low spasticity SCI subjects
Number of subjects: 20
Study 12398427 — intervention group
Group type: EXPERIMENTAL
Intervention: High spasticity SCI subjects
Number of subjects: 20
Study 12398427 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately spastic SCI subjects
Number of subjects: 20
Study 12398427 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 20
Study 10604885 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH)
Number of subjects: 30
Study 10604885 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH)
Number of subjects: 30
Study 10604885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8959681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallimustine 750 micrograms/m2 intravenously every 4 weeks
Number of subjects: 14
Study 8959681 — intervention group
Group type: EXPERIMENTAL
Intervention: Tallimustine
Number of subjects: 14
Study 1683301 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg levonorgestrel tablets (two types)
Number of subjects: 361
Study 7241391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7241391 — intervention group
Group type: COMPARATOR
Intervention: No specific treatment
Number of subjects: 63
Study 7241391 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 2,3‐dimercaptopropane‐1‐sulfonate
Number of subjects: 63
Study 7241391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiolated resin
Number of subjects: 63
Study 7241391 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐penicillamine
Number of subjects: 63
Study 7241391 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetyl‐DL‐penicillamine
Number of subjects: 63
Study 29254421 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive speed of processing training (SPT)
Number of subjects: 49
Study 29254421 — intervention group
Group type: COMPARATOR
Intervention: Active control group of cognitive stimulation
Number of subjects: 49
Study 27939188 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard‐length CWMT (45‐min/session, 25 sessions)
Number of subjects: 135
Study 27939188 — intervention group
Group type: EXPERIMENTAL
Intervention: Shortened‐length CWMT (15-min/session, 25 sessions)
Number of subjects: 135
Study 27939188 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group
Number of subjects: 135
Study 25749644 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 14171
Study 23603450 — intervention group
Group type: EXPERIMENTAL
Intervention: High Perseverance of Effort subscale
Number of subjects: 40
Study 23603450 — intervention group
Group type: EXPERIMENTAL
Intervention: High Consistency of Interest subscale
Number of subjects: 40
Study 21797102 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 100
Study 21797102 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg
Number of subjects: 100
Study 20017943 — intervention group
Group type: EXPERIMENTAL
Intervention: Daivobet
Number of subjects: 24
Study 20017943 — intervention group
Group type: EXPERIMENTAL
Intervention: calcipotriol
Number of subjects: 24
Study 20017943 — intervention group
Group type: COMPARATOR
Intervention: betamethasone
Number of subjects: 24
Study 18074501 — intervention group
Group type: EXPERIMENTAL
Intervention: liposuction plus diet
Number of subjects: 12
Study 18074501 — intervention group
Group type: COMPARATOR
Intervention: diet‐only
Number of subjects: 12
Study 15069173 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calcium dialysate (LCD; calcium: 1.25 mmol/l)
Number of subjects: 44
Study 15069173 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium dialysate (SCD; calcium: 1.75 mmol/l)
Number of subjects: 44
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 1.0401
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 1.0402
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 1.0403
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: Cor a 1.0404
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: rCor a 1.0401
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: rCor a 1.0402
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: rCor a 1.0403
Number of subjects: 43
Study 11750653 — intervention group
Group type: EXPERIMENTAL
Intervention: rCor a 1.0404
Number of subjects: 43
Study 11750653 — intervention group
Group type: COMPARATOR
Intervention: Native hazelnut extract
Number of subjects: 43
Study 11038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40
Study 11038831 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 40
Study 11038831 — intervention group
Group type: COMPARATOR
Intervention: Enflurane
Number of subjects: 40
Study 11038831 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 7939388 — intervention group
Group type: EXPERIMENTAL
Intervention: NOVA ISE for IMg2+
Number of subjects: 0
Study 7939388 — intervention group
Group type: EXPERIMENTAL
Intervention: KONE ISE for IMg2+
Number of subjects: 0
Study 7939388 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized patients (randomly selected)
Number of subjects: 0
Study 7939388 — intervention group
Group type: COMPARATOR
Intervention: Patients with coronary heart disease, rectal cancer, and multiple sclerosis
Number of subjects: 0
Study 2526993 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose omega-3 fatty acid (N3FA) supplementation (4.5 g/day)
Number of subjects: 194
Study 2526993 — intervention group
Group type: COMPARATOR
Intervention: No N3FA (control)
Number of subjects: 194
Study 2526993 — intervention group
Group type: EXPERIMENTAL
Intervention: N3FA supplementation (4.5 g/day)
Number of subjects: 194
Study 848927 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis
Number of subjects: 196
Study 848927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 31634905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate (4 g; n=415)
Number of subjects: 735
Study 31634905 — intervention group
Group type: COMPARATOR
Intervention: Cryoprecipitate (10 units; n=412)
Number of subjects: 735
Study 28736559 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine injections (1,000 mg 3 times weekly after hemodialysis)
Number of subjects: 60
Study 28736559 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocarnitine injections
Number of subjects: 60
Study 28736559 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 60
Study 26371709 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 haplotype carriers
Number of subjects: 500
Study 26371709 — intervention group
Group type: COMPARATOR
Intervention: Control group (fertile couples)
Number of subjects: 500
Study 26371709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RSA (live birth vs no live birth)
Number of subjects: 500
Study 26371709 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RSA (positive vs negative for known risk factors)
Number of subjects: 500
Study 26371709 — intervention group
Group type: EXPERIMENTAL
Intervention: Male and female partners in each group
Number of subjects: 500
Study 26371709 — intervention group
Group type: EXPERIMENTAL
Intervention: M2 haplotype carriers with other risk factors
Number of subjects: 500
Study 23851972 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) as an adjunct to usual care
Number of subjects: 469
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 in cervical secretion with expectant management
Number of subjects: 508
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score with expectant management
Number of subjects: 508
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length with expectant management
Number of subjects: 508
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP-1 in cervical secretion with induction of labor
Number of subjects: 508
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop score with induction of labor
Number of subjects: 508
Study 21275916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical length with induction of labor
Number of subjects: 508
Study 20007408 — intervention group
Group type: EXPERIMENTAL
Intervention: S. repens (Saw palmetto)
Number of subjects: 3300
Study 20007408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3300
Study 20007408 — intervention group
Group type: EXPERIMENTAL
Intervention: P. africanum (African plum tree)
Number of subjects: 3300
Study 20007408 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocking drug
Number of subjects: 3300
Study 16411993 — intervention group
Group type: EXPERIMENTAL
Intervention: Kneeling position
Number of subjects: 271
Study 16411993 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 271
Study 15630469 — intervention group
Group type: EXPERIMENTAL
Intervention: three successive fixed therapy interruptions (TIs) of 2, 4, and 6 weeks, with intervening resumption of therapy for 4 weeks before subsequent interruption
Number of subjects: 42
Study 15630469 — intervention group
Group type: COMPARATOR
Intervention: 40 weeks of continuous therapy
Number of subjects: 42
Study 11264969 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 9222086 — intervention group
Group type: EXPERIMENTAL
Intervention: ET-1 (0 (saline), 1.25, 2.5 and 5.0 ng/kg/min; 20 minutes per dose)
Number of subjects: 10
Study 9222086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8490471 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management
Number of subjects: 184
Study 8490471 — intervention group
Group type: COMPARATOR
Intervention: Mild exercise
Number of subjects: 184
Study 3819261 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine mesylate (DEM, Hydergine) at 6 mg per day, administered orally for 12 weeks
Number of subjects: 41
Study 3819261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 31728731 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitizing agents (Vertise Flow, Universal Dentin Sealant, Clearfil Protect Bond, Flor‐Opal Varnish)
Number of subjects: 40
Study 31728731 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy patients)
Number of subjects: 40
Study 28448426 — intervention group
Group type: EXPERIMENTAL
Intervention: Filorexant 10 mg nightly
Number of subjects: 182
Study 28448426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 27989253 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (60 ml dose)
Number of subjects: 27
Study 27989253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 24048913 — intervention group
Group type: COMPARATOR
Intervention: Normal training group (G1) - maintained the same training program (8-repetitions × 4-sets with 4-min recovery)
Number of subjects: 20
Study 24048913 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapering group (G2) - performed reduced training volume (3 sets/exercise; -22%)
Number of subjects: 20
Study 23737453 — intervention group
Group type: EXPERIMENTAL
Intervention: Almorexant 200 mg once daily for 10 days with warfarin 25 mg on day 5
Number of subjects: 14
Study 23737453 — intervention group
Group type: COMPARATOR
Intervention: Warfarin 25 mg on day 1
Number of subjects: 14
Study 20502393 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner treatment (PDPT) with metronidazole
Number of subjects: 252
Study 18443798 — intervention group
Group type: EXPERIMENTAL
Intervention: Early detection and treatment of amblyopia; specific intervention details not available.
Number of subjects: 0
Study 18443798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized controlled studies; specific intervention details not available.
Number of subjects: 0
Study 16636989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented product containing Lactobacillus gasseri CECT 5714 and Lactobacillus coryniformis CECT 5711
Number of subjects: 0
Study 16636989 — intervention group
Group type: COMPARATOR
Intervention: Standard yogurt (control)
Number of subjects: 0
Study 12819517 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for nelfinavir
Number of subjects: 147
Study 12819517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TDM) for nelfinavir
Number of subjects: 147
Study 12819517 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for indinavir
Number of subjects: 147
Study 12819517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TDM) for indinavir
Number of subjects: 147
Study 12819517 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring (TDM) for both drugs
Number of subjects: 147
Study 12819517 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TDM) for both drugs
Number of subjects: 147
Study 12135821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial home visit programme consisting of five home visits by a community nurse over a period of 1 year
Number of subjects: 0
Study 10099058 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily (clinical dosage)
Number of subjects: 0
Study 10099058 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 200 mg once daily
Number of subjects: 0
Study 10099058 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 600 mg (200 mg three times daily)
Number of subjects: 0
Study 8030631 — intervention group
Group type: EXPERIMENTAL
Intervention: Various statistical methods for intervention studies
Number of subjects: 0
Study 8030631 — intervention group
Group type: EXPERIMENTAL
Intervention: Data from a school-based smoking cessation trial
Number of subjects: 0
Study 3057847 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine and emergency transtelephonic follow‐up and ECG monitoring
Number of subjects: 1004
Study 3057847 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Number of subjects: 1004
Study 3057847 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient post‐myocardial infarction transtelephonic surveillance program
Number of subjects: 1004
Study 31423939 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 23
Study 31423939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 25725366 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 99
Study 25725366 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterolateral Fusion (PLF)
Number of subjects: 99
Study 25725366 — intervention group
Group type: COMPARATOR
Intervention: Control Group (Healthy Volunteers)
Number of subjects: 99
Study 25725366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PLIF and PLF
Number of subjects: 99
Study 23043681 — intervention group
Group type: EXPERIMENTAL
Intervention: Predischarge TSB screening
Number of subjects: 1157
Study 23043681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined clinical risk factors and age-adjusted TSB
Number of subjects: 1157
Study 23043681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined screening (clinical risk factors + TSB)
Number of subjects: 1157
Study 23043681 — intervention group
Group type: EXPERIMENTAL
Intervention: TcB/TSB combined with GA alone
Number of subjects: 1157
Study 21753062 — intervention group
Group type: EXPERIMENTAL
Intervention: iTFA
Number of subjects: 61
Study 21753062 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA
Number of subjects: 61
Study 21753062 — intervention group
Group type: COMPARATOR
Intervention: Control (oleic acid)
Number of subjects: 61
Study 19137363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-track treatment
Number of subjects: 101
Study 19137363 — intervention group
Group type: COMPARATOR
Intervention: Traditional treatment
Number of subjects: 101
Study 19137363 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 101
Study 17117182 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine
Number of subjects: 552
Study 17117182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 552
Study 16929590 — intervention group
Group type: EXPERIMENTAL
Intervention: Silybum marianum 160 mg orally three times a week for four weeks
Number of subjects: 34
Study 16929590 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (control)
Number of subjects: 34
Study 11336929 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin therapy (6 mg per square meter of body surface area) administered by intravenous infusion over 10 minutes, followed by laser treatment at 689 nm.
Number of subjects: 339
Study 11336929 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy (5% dextrose in water) administered by intravenous infusion over 10 minutes, followed by sham laser treatment.
Number of subjects: 339
Study 9153366 — intervention group
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate adhesive
Number of subjects: 130
Study 9153366 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 130
Study 7959281 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stapling technique
Number of subjects: 15
Study 7959281 — intervention group
Group type: COMPARATOR
Intervention: Traditional clamp, cut, and suture ligation technique
Number of subjects: 15
Study 7959281 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 15
Study 3304409 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg twice daily
Number of subjects: 38
Study 3304409 — intervention group
Group type: COMPARATOR
Intervention: Routine postoperative therapy alone
Number of subjects: 38
Study 31486230 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of canagliflozin (100 mg/d) and teneligliptin (20 mg/d)
Number of subjects: 99
Study 31486230 — intervention group
Group type: COMPARATOR
Intervention: SGLT2 inhibitor monotherapy (canagliflozin 100 mg/d)
Number of subjects: 99
Study 31198139 — intervention group
Group type: EXPERIMENTAL
Intervention: CPIS-guided therapy
Number of subjects: 166
Study 31198139 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinical experience of chief physician)
Number of subjects: 166
Study 31198139 — intervention group
Group type: EXPERIMENTAL
Intervention: CPIS group
Number of subjects: 166
Study 31198139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 28278354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (a‐tDCS) at 2 mA for 20 min
Number of subjects: 30
Study 28278354 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (tDCS turned off after 30 seconds)
Number of subjects: 30
Study 28278354 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 30
Study 26686794 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinacalcet in addition to conventional therapy
Number of subjects: 0
Study 26686794 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 0
Study 23771841 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally specific pilot clinic for Asian Americans
Number of subjects: 109
Study 23771841 — intervention group
Group type: COMPARATOR
Intervention: Standard care for white patients with type 2 diabetes
Number of subjects: 109
Study 21649779 — intervention group
Group type: EXPERIMENTAL
Intervention: Steerable sheath (group S)
Number of subjects: 80